Filing Flows › Crescent Biopharma (CBIO) › Recalls, complaints & regulation
Crescent Biopharma (CBIO): clinical trials
Crescent Biopharma (CBIO) beyond its filings: 2 active clinical trials.
Crescent Biopharma's latest quarter
Crescent Biopharma, Q1 2026: revenue $1.0M, net loss $23.3M, operating cash flow −$8.9M. The chart follows the revenue to costs, profit and cash.
Questions
How many clinical trials does Crescent Biopharma have?
2 active studies on ClinicalTrials.gov, 0 in phase 3.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.